Matinas BioPharma Holdings, Inc.
MTNB
$1.65
$0.042.36%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -65.89% | -42.21% | -21.10% | -13.41% | -8.78% |
| Gross Profit | 65.89% | 42.21% | 14.64% | -1.51% | -15.96% |
| SG&A Expenses | -24.87% | -19.61% | -15.86% | -14.21% | -7.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.65% | -32.71% | -18.91% | -13.75% | -8.29% |
| Operating Income | 48.65% | 32.71% | 15.17% | 5.78% | -4.74% |
| Income Before Tax | 14.07% | 13.29% | -6.05% | 0.61% | -10.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.42% | 13.63% | -5.71% | 0.61% | -10.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.42% | 13.63% | -5.71% | 0.61% | -10.85% |
| EBIT | 48.65% | 32.71% | 15.17% | 5.78% | -4.74% |
| EBITDA | 48.72% | 32.84% | 15.33% | 5.81% | -4.82% |
| EPS Basic | 24.31% | 25.65% | 5.44% | 6.98% | -7.12% |
| Normalized Basic EPS | 52.82% | 40.55% | 21.64% | 6.98% | -7.12% |
| EPS Diluted | 24.31% | 25.65% | 5.44% | 6.98% | -7.12% |
| Normalized Diluted EPS | 52.82% | 40.55% | 21.64% | 6.98% | -7.12% |
| Average Basic Shares Outstanding | 12.62% | 16.21% | 11.96% | 7.91% | 3.92% |
| Average Diluted Shares Outstanding | 12.62% | 16.21% | 11.96% | 7.91% | 3.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |